Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBelite Bio Inc ADR

Belite Bio Inc ADR

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
152.17 USD -1.50 ( 0.98%)
Last update at 2026-11-03T21:00:00Z
VOLUME
149864
Market Cap
6603.47M

Momentum Score

…

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
152.03
Low
157.47
High
52 Week Price Range
56.10
Low
200.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Belite Bio Inc. is a small, publicly listed biopharmaceutical company with limited recent public disclosures that appears positioned on developing treatments for rare and metabolic disorders. Long-term growth drivers may include clinical progress in orphan indications, regulatory incentives for rare-disease therapies, and partnering or licensing outcomes that could support commercialization. Investors may find potential upside if development programs advance because orphan indications often have clearer regulatory pathways and premium pricing dynamics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
153.67
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.00
ROE
-16.94%
Net Debt
-352.50M
ROCE
-10.93%
Diluted EPS TTM
-2.31

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -77.61M -36.14M -31.62M -12.65M -9.67M
Net income -77.61M -36.14M -31.63M -12.47M -9.79M
Selling general administrative 38.83M 10.06M 6.82M 3.95M 2.38M
Selling and marketing expenses - - 0.40M - -
Gross profit - -0.45M -0.40M - -
Reconciled depreciation 0.46M 0.45M 0.40M 0.20M 0.03M
Ebit - -36.12M -31.60M -12.82M -9.80M
Ebitda -84.21M -35.67M -31.20M -12.43M -9.64M
Depreciation and amortization - 0.45M 0.40M 0.39M 0.16M
Operating income -84.21M -40.00M -31.67M -12.82M -9.80M
Other operating expenses 84.21M 40.00M 31.67M 12.82M 9.80M
Interest expense 0.00M 0.02M 0.03M 0.02M 0.01M
Tax provision 0.00M 0.01M 0.01M 0.00M 0.00M
Interest income 6.64M 3.74M 0.07M 0.02M 0.01M
Net interest income 6.64M 3.72M 0.05M 0.01M 0.01M
Income tax expense - 0.01M 0.01M -0.17M 0.13M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 84.21M 40.00M 31.67M 12.82M 9.80M
Cost of revenue - 0.45M 0.40M - -
Total other income expense net 6.60M 3.86M 0.04M 0.17M 0.13M
Net income from continuing ops -77.61M -36.14M -31.63M -12.65M -9.67M
Net income applicable to common shares - - - - -9.67M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 780.56M 152.13M 94.64M 44.27M 18.35M
Intangible assets 4.92M 3.99M 3.23M - -
Other current assets 1.13M 1.33M 0.92M 0.72M 0.06M
Total liab 10.07M 6.31M 4.21M 2.77M 33.44M
Total stockholder equity 770.49M 145.82M 90.43M 41.50M -15.09M
Deferred long term liab - - - - 0.81M
Other current liab 9.64M 5.77M 3.33M 1.91M 1.64M
Common stock 0.00M 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -185.26M -107.65M -71.50M -39.87M -27.22M
Other assets - - 0.00M - 0.82M
Cash 352.93M 31.68M 88.16M 42.09M 17.34M
Total current liabilities 9.88M 6.05M 3.63M 2.10M 1.64M
Net debt -352.50M -31.14M -87.27M -41.22M -17.34M
Short term debt 0.24M 0.28M 0.31M 0.20M -
Short long term debt total 0.43M 0.54M 0.89M 0.87M -
Other stockholder equity 956.28M 254.12M 162.31M 81.76M 12.32M
Property plant equipment - - - - 0.09M
Total current assets 494.27M 147.07M 89.94M 42.81M 17.43M
Long term investments 280.17M 0.00M - - -
Net tangible assets - - - - -15.09M
Short term investments 139.49M 113.47M - - -
Net receivables 0.72M 0.59M 0.87M 0.02M 0.02M
Inventory - - - -0.02M -
Accumulated other comprehensive income -0.54M -0.66M -0.37M -0.39M -0.20M
Non currrent assets other 0.42M 0.10M 0.17M 0.09M 0.82M
Non current assets total 286.28M 5.06M 4.70M 1.47M 0.92M
Capital lease obligations 0.43M 0.54M 0.89M 0.87M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -304.93M -110.57M -0.06M -0.39M -0.06M
Change to liabilities - - - - 0.04M
Total cashflows from investing activities -305.11M -110.57M -0.06M - -0.06M
Total cash from financing activities 663.23M 83.59M 75.96M 36.96M -0.58M
Change to operating activities - - - - 0.59M
Net income -77.61M -36.14M -31.63M -12.65M -9.67M
Change in cash 321.25M -56.48M 46.07M 24.75M -8.27M
Begin period cash flow 31.68M 88.16M 42.09M 17.34M 25.62M
End period cash flow 352.93M 31.68M 88.16M 42.09M 17.34M
Total cash from operating activities -36.99M -29.23M -29.84M -11.46M -7.47M
Issuance of capital stock 182.02M 42.24M 55.19M 0.00M 0.00M
Depreciation 0.46M 0.45M 0.40M 0.20M 0.03M
Other cashflows from investing activities - -0.04M - - -
Change to account receivables -0.07M 0.07M -0.07M - -
Other cashflows from financing activities 370.37M 41.36M -1.23M 36.96M -0.58M
Change to netincome - - - - 1.52M
Capital expenditures 0.18M 0.15M 0.06M 0.39M 0.07M
Change in working capital 2.55M 1.13M -2.43M -0.49M 0.64M
Stock based compensation 38.92M 8.99M 3.82M 1.48M 1.53M
Other non cash items -1.31M -3.66M 4.69M - -0.01M
Free cash flow -37.17M -29.39M -29.90M -11.85M -7.55M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
BLTE
Belite Bio Inc ADR		 -1.50
0.98%		 152.17 - 227.27 - 8.57 -35.61
NVO
Novo Nordisk A/S		 -0.24
0.61%		 40.20 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 -21.28
3.85%		 531.87 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 12.10
1.26%		 973.36 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Belite Bio Inc ADR

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

12750 High Bluff Drive, San Diego, CA, United States, 92130

858 246 6240

https://www.belitebio.com

41

Name Title Year Born
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of Directors & CEO 1978
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director 1984
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer 1966
Ms. Ching-Chen Chiu M.Sc. VP of Clinical Operations 1970
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO 1979
Mr. Hao-Yuan Chuang C.F.A., F.R.M., M.B.A. CFO & Director 1985
Dr. Nathan L. Mata Ph.D. Chief Scientific Officer 1967
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer & Member of Ophthalmology Clinical Advisory Board NA
Dr. Yu-Hsin Lin M.B.A., Ph.D. Chairman of the Board of Directors & CEO 1978
Dr. Hendrik P.N. Scholl M.A., M.D., Ph.D. Chief Medical Officer 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…